Allergan Company Profile
What is the competitive landscape for ALLERGAN
ALLERGAN has sixty-five approved drugs.
Summary for Allergan
| US Patents: | 0 |
| Tradenames: | 61 |
| Ingredients: | 47 |
| NDAs: | 65 |
| Patent Litigation for Allergan: | See patent lawsuits for Allergan |
| PTAB Cases with Allergan as patent owner: | See PTAB cases with Allergan as patent owner |
Drugs and US Patents for Allergan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Herbert | AEROSEB-DEX | dexamethasone | AEROSOL;TOPICAL | 083296-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Allergan | CHLOROPTIC-P S.O.P. | chloramphenicol; prednisolone | OINTMENT;OPHTHALMIC | 061188-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Allergan | THYROLAR-0.5 | liotrix (t4;t3) | TABLET;ORAL | 016807-005 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Allergan | FML-S | fluorometholone; sulfacetamide sodium | SUSPENSION/DROPS;OPHTHALMIC | 019525-001 | Sep 29, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Allergan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-008 | Apr 20, 2007 | 5,202,128 | ⤷ Start Trial |
| Allergan | PROPINE | dipivefrin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018239-001 | Approved Prior to Jan 1, 1982 | 3,839,584 | ⤷ Start Trial |
| Allergan | OXYTROL | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 021351-002 | Feb 26, 2003 | 6,743,441 | ⤷ Start Trial |
| Allergan | SANCTURA XR | trospium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 022103-001 | Aug 3, 2007 | 7,759,359 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
| ➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
| ➤ Subscribe | Ophthalmic Solution | 0.30% | ➤ Subscribe | 2007-07-19 |
| ➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
| ➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2009-03-02 |
| ➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2008-10-14 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
